Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Senesco commences dosing in SNS01-T Phase 1b/2a clinical study for multiple myeloma

Senesco Technologies, Inc. today announced the initiation of patient dosing in its Phase 1b/2a clinical study of SNS01-T at the Mayo Clinic in Rochester, MN. The study is an open-label, multiple-dose, dose-escalation study which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.

3 Nov 2011

Age is no longer a barrier to allogeneic stem cell transplantation

Age alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That's the conclusion of the first study summarizing long-term outcomes from a series of prospective clinical trials of patients age 60 and over who were treated with the mini-transplant, a "kinder, gentler" form of allogeneic (donor cell) stem cell transplantation developed at Fred Hutchinson Cancer Research Center.

2 Nov 2011

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.

31 Oct 2011

Scientists challenge theory about why chemotherapy agents target cancer

Challenging a half-century-old theory about why chemotherapy agents target cancer, scientists at Dana-Farber Cancer Institute have devised a test that can predict how effective the drugs will be by determining whether a patient's tumor cells are already "primed" for death.

28 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.

14 Oct 2011

Cylene advances preclinical development of CX-5461 for treatment of cancer

Cylene Pharmaceuticals, Inc. has advanced its targeted, non-genotoxic, activator of p53 for the treatment of leukemias, lymphomas and multiple myeloma through formal preclinical development, the Company announced today.

14 Oct 2011

Adaptimmune announces new board appointments as clinical programmes get underway

Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director.

3 Oct 2011

EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer

EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.

3 Oct 2011

Winner of 'The Voice' to perform at MMRF Fall Gala on October 29

The Multiple Myeloma Research Foundation (MMRF) announced today that Javier Colon, winner of NBC's The Voice, will join the lineup of featured artists performing a tribute concert celebrating music industry icon Stevie Wonder at the MMRF Fall Gala, to be held October 29, 2011, at the Hyatt Regency Greenwich in Old Greenwich, Connecticut.

1 Oct 2011

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Geneticists have discovered that a gene involved in the modification of ribonucleic acid (RNA) is mutated in a significant proportion of people with a collection of blood cancers called myelodysplastic syndromes.

27 Sep 2011

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.

26 Sep 2011

Study identifies areas for cancer care cost and quality improvements

With cancer care costs rising at an unprecedented rate, The US Oncology Network, one of the nation's largest networks of community-based oncologists dedicated to advancing cancer care in America, reported a study that identified areas where both the cost and quality of care could be improved.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

23 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

John Theurer Cancer Center to join MMRF's Personalized Medicine Initiative

The John Theurer Cancer Center at Hackensack University Medical Center, a top 50 U.S. News best hospital for cancer, is one of the first four clinical sites enrolling patients in a landmark study designed to uncover the molecular segments and variations of multiple myeloma.

22 Sep 2011

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Senesco commences dosing in SNS01-T Phase 1b/2a clinical study for multiple myeloma

Age is no longer a barrier to allogeneic stem cell transplantation

Takeda receives FDA approval for VELCADE sNDA to treat MM

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Scientists challenge theory about why chemotherapy agents target cancer

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

Cylene advances preclinical development of CX-5461 for treatment of cancer

Adaptimmune announces new board appointments as clinical programmes get underway

EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer

Winner of 'The Voice' to perform at MMRF Fall Gala on October 29

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Study identifies areas for cancer care cost and quality improvements

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

John Theurer Cancer Center to join MMRF's Personalized Medicine Initiative

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in